Asymchem is a USFDA inspected contract development and manufacturing organization focused on developing practical and sustainable processes for both clinical phase and commercial scale projects in the biopharmaceutical industry.
With state-of-the-art facilities and strong expertise in a number of niche technologies, such as continuous flow,biotransformation, beta lactam containment and the development and manufacturing of peptides and potent API, Asymchem has – for over 20 years – continued to invest in the latest technologies so that clients can benefit from safe, efficient and environmentally-sustainable manufacturing processes. Added to this Asymchem maintains a strong commitment to providing outstanding levels of customer service and satisfaction and offers every client a tailored, highly-flexible approach to project management.
Suzhou BioBAY & MING BIOVENTURES
Suzhou BioBAY is located in southwest of Suzhou Industrial Park(SIP),and is the key driver of life science innovation for SIP. Being the most competitive biotech park in China, BioBAY has incubated thousands of leading innovative companies in the last 10 years. Among which, RMB 40 million of venture capital was raised, and 13 companies are listed. Now more than 400 high-tech innovative companies covering drug discovery, medical device(including IVD），bio technology, CRO, nanotechnology, investment and service have been located in BioBAY, and more than 10000 scientists and professions have come to join this dynamic innovative community.
Ming BioVentures is jointly established by BioBAY and SIPC (also known as Chinese Consortium, with total assets of more than RMB 30 billion), is operated by a professional market-based team. The first fund of Ming BioVentures has raised RMB 500 million, specializing in the venture capital investments of early and growth stages companies in new drugs, medical devices, diagnostics. Ming BioVentures focuses on the businesses with unmet clinical needs, high growth potentials and strong entrepreneurial management teams. Since established in July 2018, Ming BioVentures has successfully invested several innovative companies, including ArkBio，Zenith Medical，and Endoclot Medical.
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
Morningside Ventures is Morningside Group’s venture arm founded by the Chan Family of Hong Kong in 1986, focused on making early stage healthcare/life science investments cross border and across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc.
Morningside Ventures is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.
Deloitte is one of the world’s largest networks of accounting and consulting firms (“Big 4”). Deloitte is the brand under which about 286,200 dedicated professionals in independent firms throughout the world collaborate to provide audit, consulting, tax, and advisory services to many of the world’s most admired brands, including 85% of the Fortune 500. Our people work across more than 20 industry sectors with one purpose: to deliver measurable, lasting results. We help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society. Clients count on Deloitte to help them transform uncertainty into possibility and rapid change into lasting progress. Our people know how to anticipate, collaborate, and innovate, and create opportunity from even the unforeseen obstacle.
Exclusive Sponsor-Law Firm
Cooley is a full service global law firm, having more than 900 lawyers across 13 offices in China, Europe and the United States. For over 40 years, Cooley has played an instrumental role in the growth of many of the most sophisticated companies in the life sciences industry, focusing on corporate partnering, licensing, complex mergers, acquisitions and disposition transactions, local and cross-border intellectual property issues, regulatory counselling, capital markets, supply and distribution arrangements and other commercial transactions. Our experience representing life sciences companies and investors also gives us insight into financings of companies at all stages of development.
We have been advising on Greater China-related matters over three decades and recently expanded our Asia-Pacific presence by launching the Beijing office. It is Cooley’s 13th office worldwide and its second in China, having opened in Shanghai in 2011.